Headlines about Eli Lilly and (NYSE:LLY) have been trending somewhat positive on Tuesday, Accern reports. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Eli Lilly and earned a coverage optimism score of 0.14 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.2123163528249 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the media headlines that may have effected Accern Sentiment’s analysis:
- Health and Human Services chief leaves hospital after overnight stay for treatment of infection (washingtonpost.com)
- Health and Human Services secretary discharged after overnight stay at hospital (washingtonpost.com)
- Boehringer Ingelheim and Lilly announce an academic collaboratio – KAIT Jonesboro, AR – Region 8 News, weather, sports (kait8.com)
- Insulin Pen Market Analysis in 10 Major Markets – Leading Players are Novo Nordisk, Eli Lilly, Sanofi, Owen Mumford, Ypsomed and Biocon Ltd. (medgadget.com)
- Eli Lilly and Co (LLY) Short Interest Down 26.5% in March (americanbankingnews.com)
A number of equities research analysts recently issued reports on the company. Argus raised Eli Lilly and from a “hold” rating to a “buy” rating and upped their target price for the company from $85.52 to $115.00 in a research note on Friday, January 5th. Goldman Sachs lowered Eli Lilly and from a “buy” rating to a “neutral” rating and upped their target price for the company from $86.98 to $95.00 in a research note on Tuesday, January 16th. Jefferies Group set a $100.00 target price on Eli Lilly and and gave the company a “buy” rating in a research note on Tuesday, January 16th. Credit Suisse Group lowered Eli Lilly and from a “neutral” rating to an “underperform” rating and set a $82.00 price target on the stock. in a research note on Monday, January 22nd. Finally, BMO Capital Markets increased their price target on Eli Lilly and from $73.00 to $74.00 and gave the stock an “underperform” rating in a research note on Thursday, February 1st. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $93.16.
NYSE LLY traded down $0.22 during trading hours on Tuesday, hitting $79.90. The company had a trading volume of 1,355,476 shares, compared to its average volume of 4,673,977. Eli Lilly and has a fifty-two week low of $73.69 and a fifty-two week high of $89.09. The company has a market cap of $87,341.06, a P/E ratio of 18.65, a P/E/G ratio of 1.49 and a beta of 0.26. The company has a current ratio of 1.32, a quick ratio of 1.01 and a debt-to-equity ratio of 0.85.
Eli Lilly and (NYSE:LLY) last announced its earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.06. The company had revenue of $6.16 billion during the quarter, compared to the consensus estimate of $5.93 billion. Eli Lilly and had a positive return on equity of 33.01% and a negative net margin of 0.89%. The company’s revenue was up 7.0% on a year-over-year basis. During the same period last year, the firm earned $0.95 earnings per share. sell-side analysts forecast that Eli Lilly and will post 4.87 EPS for the current fiscal year.
In other news, SVP Jeffrey N. Simmons sold 9,625 shares of the stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $81.12, for a total transaction of $780,780.00. Following the transaction, the senior vice president now owns 152,120 shares of the company’s stock, valued at $12,339,974.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Donald A. Zakrowski sold 860 shares of the stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $76.50, for a total transaction of $65,790.00. The disclosure for this sale can be found here. Insiders have sold 15,261 shares of company stock valued at $1,225,085 over the last 90 days. Insiders own 0.11% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://ledgergazette.com/2018/04/17/eli-lilly-and-lly-given-daily-coverage-optimism-rating-of-0-14.html.
About Eli Lilly and
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.